In 2 separate studies, patients taking TYSABRI reported statistically significant improvements in quality of life, with regard to health-related quality of life (HRQoL) and Quality of Life in Neurological Disorders (Neuro-QoL) scores
Adapted from the American Medical Association by Wiley-Liss, Inc.
Bold rows with highlighted values: statistically significant compared with placebo.
Baseline scores and changes from baseline at Weeks 24, 52, and 104 are shown for all SF-36 scales.
This study was funded by Biogen.
Bold rows with highlighted values are statistically significant.
eDue to reconfiguration of the Multiple Sclerosis Performance Test during the course of this study, 14 of the 164 patients did not provide responses to two of the Neuro-QoL domains—(1) positive affect and well-being and (2) emotional and behavioral dyscontrol—resulting in a total of 150 individual patient responses for these two domains.
fRate and CI are based on a multivariate-adjusted mixed-effects regression model.